Skip to content
Competitive Intelligence

Pricing & Positioning Comparison

Where competitors actually price, sit and win.

A defensible cross-competitor pricing and positioning comparison framework — across geographies, indications and channels — for launch and competitive teams.

Decision angle

"How should we price and position against a fully-mapped competitor set?"

TL;DR

Useful pricing comparison goes beyond list price to net price, gross-to-net, payer placement, contracting strategy and country-by-country positioning.

Pricing comparison done badly is a list-price grid. Done well, it is a country-by-country, net-price, multi-layer positioning model that drives launch and brand decisions.

Key insights

What we’re seeing in the data.

01

List price hides net economics

Net price after rebates, GPO contracts and payer deals is the only meaningful comparison.

02

Country pricing diverges sharply

EU reference pricing networks force coordination; APAC requires localized strategy.

03

Positioning is multi-layer

Clinical positioning, payer positioning and patient positioning often point in different directions.

04

Indications-based pricing emerging

Same molecule, different prices by indication — increasingly accepted in EU.

Net
Always model net price
Not list
Geo
Country-by-country
Required
3
Positioning layers
HCP/Payer/Patient
Q
Refresh cadence
Quarterly
Decision framework

How to think about it.

  1. 01

    Map list and net by competitor

    Use IQVIA, claims and contracting intelligence.

  2. 02

    Decompose by geography

    Country-specific list, net, payer placement.

  3. 03

    Score positioning layers

    Clinical, payer, patient narratives.

  4. 04

    Forecast price erosion

    LoE, biosimilar entry, indication expansion.

  5. 05

    Run scenario pricing

    Multiple launch-price scenarios with peak NPV.

Considerations

What separates a good answer from a defensible one.

Confidential rebates

Net pricing is opaque — model ranges.

HTA outcomes

NICE / G-BA decisions cascade through reference pricing.

Bundled contracting

Bundled deals shift net economics non-obviously.

Indication-based pricing

Per-indication pricing changes forecast.

Sources & tools

Where the signal comes from.

IQVIA pricing data NICE / G-BA / HAS reports Cortellis pricing & access Internal contracting data
FAQ

Common questions.

Why isn’t list price enough?

Net is often 30–60% below list. Strategy off list price is structurally wrong.

How do you handle confidential rebates?

Triangulate from public filings, payer interviews and gross-to-net disclosures with explicit ranges.

Want this answered on your data?

We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.

Talk to a strategist